BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$7.95 USD
-0.19 (-2.33%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $7.96 +0.01 (0.13%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
BCRX 7.95 -0.19(-2.33%)
Will BCRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BCRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BCRX
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for
BCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth
Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?
Ensign Group Boosts U.S. Presence With Idaho and Texas Facility Buyouts
Other News for BCRX
BioCryst Pharmaceuticals Q2 2025 Earnings Preview
Earnings Outlook For BioCryst Pharma
BioCryst appoints Charlie Gayer to succeed Jon Stonehouse as CEO
BioCryst Pharmaceuticals Announces CEO Transition | BCRX stock news
BioCryst (BCRX) Announces Leadership Transition Plan